Kuang Wayne, Desai Priya, Voloshko Alexander, Jayasekara Deepthi
Pediatrics, Los Angeles County+University of Southern California Medical Center, Los Angeles, USA.
Internal Medicine, Western University of Health Sciences, Pomona, USA.
Cureus. 2022 May 1;14(5):e24638. doi: 10.7759/cureus.24638. eCollection 2022 May.
Coronavirus disease 2019 (COVID-19) has been known to affect multiple organ systems, aside from the respiratory system. Increasing reports of post-infection neurological complications have been reported. Miller-Fisher syndrome, a rare variant of Guillain-Barré syndrome (GBS), has been reported after COVID-19 infection. We present the youngest known adult (26-year-old male) reported to have had COVID-19-associated Miller Fisher syndrome (MFS) with also the longest reported latency period (10 weeks) between infection and development of neurological symptoms (including dysphagia, horizontal diplopia, facial weakness, upper and lower extremity weakness, paresthesia). This is currently the second youngest reported case after the case of a seven-year-old child. The patient was treated with intravenous immunoglobulin and was ultimately transferred to a different facility for higher level of care. Most symptoms were resolved within four days. The patient reported resolution of neurologic symptoms with the exception of left-sided facial weakness at the one-year follow-up. As more reports of COVID-19-associated GBS and MFS appear in the future, we are likely to discover more variability than was previously known in GBS and MFS. With COVID-19 potentially affecting multiple systems, there could be increased variability to previously known conditions. Future studies may need to closely examine long-term follow-ups of patients previously diagnosed with COVID-19 as post-COVID complications become more prevalent.
2019冠状病毒病(COVID-19)已知除了会影响呼吸系统外,还会累及多个器官系统。感染后神经系统并发症的报告越来越多。米勒-费希尔综合征是格林-巴利综合征(GBS)的一种罕见变体,已有COVID-19感染后发生该综合征的报告。我们报告了已知最年轻的成年患者(26岁男性),其患有与COVID-19相关的米勒-费希尔综合征(MFS),且感染与神经症状(包括吞咽困难、水平性复视、面部无力、上下肢无力、感觉异常)出现之间的潜伏期也是报告中最长的(10周)。这是目前仅次于一名7岁儿童病例的第二年轻报告病例。该患者接受了静脉注射免疫球蛋白治疗,最终被转至另一机构接受更高水平的护理。大多数症状在四天内得到缓解。在一年的随访中,患者报告除左侧面部无力外,神经症状均已缓解。随着未来与COVID-19相关的GBS和MFS报告越来越多,我们可能会发现GBS和MFS比以前所知有更多的变异性。由于COVID-19可能影响多个系统,以前已知疾病的变异性可能会增加。随着COVID-19后并发症变得更加普遍,未来的研究可能需要密切检查先前诊断为COVID-19的患者的长期随访情况。